CTR20262853 SM-2275 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines CTR20262853 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 3 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why CTR20262853 is a hot trial to watch
Advanced Malignant Solid Neoplasm is being segmented by mechanism, treatment setting, geography and endpoint architecture. CTR20262853 is notable because it evaluates SM-2275 in a Phase 1 design sponsored by Beijing Shuoxing Biomedical Technology Co. Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | CTR20262853 |
| Official title | 一项评价SM2275在晚期实体瘤患者中的安全性、耐受性、药代动力学、药效动力学和初步疗效的单臂、开放、剂量递增和剂量扩展的I期临床研究 |
| Phase / status | Phase 1 / 进行中 （尚未招募） |
| Intervention | SM-2275 |
| Sponsor | Beijing Shuoxing Biomedical Technology Co. Ltd. |
| Geography | China |
| Enrollment | [object Object] |
| Primary endpoint | |
| Endpoint time frame | 首次给药后21天 |
| Primary completion / readout proxy | Not reported |
Protocol design and endpoint interpretation
The indexed record describes a Phase 1 study of SM-2275 in Advanced Malignant Solid Neoplasm.
Allocation is 非随机化, masking is 开放, and the intervention model is 单臂试验. Planned enrollment of [object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary endpoint (首次给药后21天) — 剂量限制性毒性，最大耐受剂量或最大给药剂量；
- Primary endpoint (试验全周期) — 根据美国国立癌症研究院不良事件通用术语标准（NCI CTCAE）6.0 版分级的不良事件和严重不良事件发生率，与研究药物的相关性，严重程度；生命体征，体格检查，12-导联心电图和实验室检查；
- Primary endpoint (试验全周期) — 综合考虑安全性、耐受性、PK、PD和有效性数据确定RP2D。
Readout outlook and evidence gap
The current protocol points to Not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: SM-2275 is indexed as Nanobody, Tetraspecific antibody, with target CD28 x EGFR x PDL1 x albumin, mechanism CD28 agonists, EGFR antagonists, PDL1 inhibitors, and global highest development status Phase 1.
Company & Deal Intelligence MCP profile: Beijing Shuoxing Biomedical Technology Co. Ltd. is resolved to a normalized organization record in Zhuhai, China. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
CTR20262853 provides a focused lens on Advanced Malignant Solid Neoplasm development. Its value will be determined by whether SM-2275 can convert the current Phase 1 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
